Compounded Tirzepatide and 503A Compounding Pharmacies
The conversation around compounding pharmacies has gained heightened attention in the current landscape of medication shortages and evolving healthcare needs. The FDA’s recent, abrupt removal and subsequent reinstatement of access to compounded tirzepatide injections (GLP-1) underscores the essential role that 503a compounding pharmacies play in facilitating patient access to essential medications in shortage.
PART II: The Gray Market of Tirzepatide Injections — A Dangerous Alternative
As access to compounded tirzepatide injections recently became increasingly restricted, many patients turned to the gray market — an underground network where medications are sold outside regulated pharmacies.
Methylene Blue and Alzheimer’s Disease
We’ve put together the studies and research on the inhibition of cytochrome oxidase, which may be the key to addressing Alzheimer’s Disease.